CD19 and diffuse large B-cell lymphoma: However, alternative, more realistic approaches for DLBCL patients with defective antigen presentation represent cellular immunotherapies, including chimeric antigen receptor (CAR) T cell therapy directed against tumor cell surface antigens, such as CD19 and CD79 [142].